Research Poster Cites Cleanascite™ for Cancer Cell Metabolism

News Release

Research Poster Cites Cleanascite™ for Cancer Cell Metabolism

MONMOUTH JUNCTION, NJ, November 2, 2016 -- Biotech Support Group reports on a recent research poster describing the simplicity and efficiency of their sample preparation technology for clearing lipids from omental explant culture system, for the study of ovarian cancer cells and intraperitoneal tumor colonization.

The citation is:

Chan, DW, Mak, SL, Ngan, HYS. The significance of lipid metabolism in peritoneal metastases of ovarian cancer. The 2016 Cold Spring Harbour Asia Conference on Cancer and Metabolism, Suzhou, China, 19-23 September 2016.

brief, the authors report that the high lipid content in ascetic fluid provides a huge energy source for ovarian cancer cells in peritoneal dissemination and intraperitoneal tumor colonization. In this study, ovarian cancer cells co-cultured with an omental explant culture system (OCM) or ascetic fluid from ovarian cancer patients exhibited an increase in in vitro cell growth, cell migration/invasion through activation of TAK1/NF-kappaB signaling cascade. The abstract states “In contrast, the oncogenic capacities of ovarian cancer cells were impaired when cultured in OCM treated with Cleanascite Lipid Removal Reagent, suggesting that the bioactive lipids in OCM are required for enhanced oncogenic capacities”.

I am very pleased that the versatility of Cleanascite™ has helped to support a new area of research, studying the metabolic changes associated with cancer. The exquisite selectivity profile of Cleanascite™ makes this possible.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to


Dr. Swapan Roy & Matthew Kuruc
Biotech Support Group LLC
1 Deer Park Drive, Suite M
Monmouth Junction NJ 08852
732-274-2866 Worldwide
800-935-0628 North America